The PARADIGM team is working to create a platform for personalized genome editing medicines – St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital shared a post on LinkedIn:
“Interested in saving the lives of children with otherwise untreatable genetic disorders? Join the St. Jude state-of-the-art genome editing initiative called PARADIGM, co-led by Shengdar Q. Tsai, who is looking for creative and motivated scientists to help develop customized genome editing medicines for young hematology patients.
The PARADIGM team is working to create a platform for personalized genome editing medicines, starting with bone marrow failure disorders, including rapid lead target discovery, engineering novel editors to address patient-specific mutations, and comprehensively assessing activity and safety. PARADIGM holds the promise of facilitating bidirectional translation of research from bench to bedside and back at St. Jude.
Help us build a future of personalized genome editing medicines. Apply now.”
Proceed to the video attached to the post.